Short
ARCA BIOPHARMA INC
NASDAQ:ABIO
Another possible short for today.
After a sharp rise on May 28, the paper could not grow any further.
All the growth has already been sold.
At 6.81 instrument faced a strong support level.
Within 3 days there were a level tests.
On June 22, the big long player managed to raise the price slightly from 6.89 to 7.52.
However, in the last trading session the short player pushed the price down again.
We can see the struggle of two strong players for the price.
It is quite possible that today the support level will be broken through in the close retest.
The safest scenario is to enter the short only after the break-down and fixing the price under the level.
If the price can't get fixed, it is not recommended to enter the short because there are obviously two strong opposite players, further struggle is possible.
Another possible short for today.
After a sharp rise on May 28, the paper could not grow any further.
All the growth has already been sold.
At 6.81 instrument faced a strong support level.
Within 3 days there were a level tests.
On June 22, the big long player managed to raise the price slightly from 6.89 to 7.52.
However, in the last trading session the short player pushed the price down again.
We can see the struggle of two strong players for the price.
It is quite possible that today the support level will be broken through in the close retest.
The safest scenario is to enter the short only after the break-down and fixing the price under the level.
If the price can't get fixed, it is not recommended to enter the short because there are obviously two strong opposite players, further struggle is possible.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.